FundedIQ
Biotechnology

PierianDx: Funding, Investors & Team (Sep 2026)

PierianDx is catalyzing global adoption of genomic sequencing in healthcare by empowering physicians in the laboratory and clinic to more effectively diagnose and treat patients with cancer and other complex diseases. PierianDx’s industry-leading genomic SaaS solutions, CAP and CLIA accredited laboratory, and shared knowledgebase are used by health systems, cancer centers and commercial laboratories worldwide driving the most integrated approach across the clinical care spectrum. From genomic sequencing and biomedical informatics in the laboratory to reporting and decision support at the patient’s bedside, PierianDx has rapidly become the trusted source of ‘wisdom’ in every advanced genomic report.

www.pieriandx.com LinkedIn St Louis, United States 101-250 employees
Biotechnology Health Care Health Diagnostics Medical
Total raised
$30.0M
Rounds
1
Latest
Undisclosed round
Nov 2021

PierianDx has raised $30.0M across 1 funding round on record, the most recent an undisclosed round of $30.0M announced in Nov 2021.

That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.

PierianDx Company Profile and Key Stats

Total funding raised
$30.0M
across 1 round on record
Funding rounds on record
1
Latest funding round
Undisclosed round
$30.0M in Nov 2021
Employees
101-250
reported band
Headquarters
St Louis, United States

Latest funding round on record: Nov 2021.

PierianDx Funding Rounds

Date
Round
Amount
Undisclosed round
$30.0M

PierianDx Founders and Leadership Team

Name
Role
Contact
Rakesh Nagarajan
CEO
Locked

Contact details for the PierianDx team: 1 of 1 has an email address on file.

Start 14-day free trial →

PierianDx Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round
4,183
$8.0M
29,981
$7.5M

PierianDx's latest round of $30.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like PierianDx in Biotechnology and St Louis

Companies Similar to PierianDx

Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…

Series E $92.5M

Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…

Series B $40.0M

Datavant is a developer of a healthcare data platform dedicated to assisting in protecting, matching, and…

Private Equity

Shennon Biotechnologies conducts a thorough examination and control of an enormous quantity of cells,…

Undisclosed round $12.0M

SeqWell’s is a biotechnology company that specializes in the fields of gene sequencing and laboratory…

Undisclosed round $960k

DermaSensor’s mission is to save lives and healthcare costs by providing easy access to effective skin cancer…

Series B $4.0M

Solstice Oncology is a clinical stage immuno-oncology company

Series A $225M

Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad…

Series F $275M

BrainChild Bio is a biotechnology company in the clinical stage that specializes in pediatric brain tumors.…

Series A $116M

Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…

Series B $65.5M

Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…

Seed $7.0M

ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…

Series C $10.0M

PierianDx Funding FAQs

What does PierianDx do?

PierianDx is catalyzing global adoption of genomic sequencing in healthcare by empowering physicians in the laboratory and clinic to more effectively diagnose and treat patients with cancer and other complex diseases. PierianDx’s industry-leading genomic SaaS solutions, CAP and CLIA accredited laboratory, and shared knowledgebase are used by health systems, cancer centers and commercial laboratories worldwide driving the most integrated approach across the clinical care spectrum. From genomic sequencing and biomedical informatics in the laboratory to reporting and decision support at the patient’s bedside, PierianDx has rapidly become the trusted source of ‘wisdom’ in every advanced genomic report.

How much funding has PierianDx raised?

PierianDx has raised $30.0M across 1 round on record. The most recent is an undisclosed round of $30.0M announced in Nov 2021.

When did PierianDx last raise funding?

PierianDx's most recent funding round on record is an undisclosed round of $30.0M, announced in Nov 2021.

Who is the CEO of PierianDx?

Rakesh Nagarajan is listed as CEO at PierianDx.

Where is PierianDx headquartered?

PierianDx is based in St Louis, Missouri, United States.

How many employees does PierianDx have?

PierianDx is in the 101-250 employee band.

How does PierianDx's funding compare to other Biotechnology startups?

PierianDx's latest round of $30.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.

About FundedIQ's PierianDx Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for PierianDx is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.

Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.